Nebulizer Delivery of Intranasal Scopolamine

Inclusion Criteria: * Male or female * Adults age 21-49 * Normal weight for body size, based on BMI table * General good health, as determined by a verbally provided medical history * Normal brief neurological exam * Renal and hepatic function within normal ranges * Able to provide written informed consent to participate Exclusion Criteria: * Drug allergies to scopolamine or other belladonna alkaloid * Use of medications within 1 week of starting the study * Use of an investigational drug within 30 days of starting the study * Tobacco smoking within the past year * Blood donation or significant blood loss within 30 days of starting the study * Significant gastrointestinal disorder (e.g. Crohn's Disease, ulcerative colitis, chronic constipation), asthma, glaucoma, prostate problems, urinary obstruction, or seizure disorders * History of alcohol or other drug abuse * Pregnancy or suspected pregnancy, or lactation (pregnancy will be confirmed with urine pregnancy testing prior to drug administration) * Consumption of grapefruit juice within 7 days of scopolamine (SCOP) administration * Nasal, nasal sinus, or nasal mucosa surgery within 90 days prior to study initiation * Other significant surgeries within 90 days * Significant deviated septum that blocks air flow in one nostril * Rhinitis, sinus infection, severe allergies, and other upper respiratory infections within 30 days prior to the study * Current use of an intranasal medication * Wheezing or other respiratory problem * Unable to consent * Prisoner